STRO

#2802
Sutro Biopharma, Inc.
34.6900 USD
+3.27%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
34.6900
34.6900
년간 변동
16.7400
36.0000
일일 변동
+3.27%
월간 변동
+42.00%
6달 변화
+99.48%
년간 변동율
+99.48%
이전 종가
33.5900
시가
34.6900
저가
34.6900
High
34.6900
양
15
전체 차트 열기

Financials

개요 성명 통계
4분기 연간
손익계산서 대차대조표 현금 흐름
값 202020212022202320242025 TTM

Sutro Biopharma Inc

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009. Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers.

뉴스